Micron Biomedical, a US-based life science company, announced on Tuesday that it has named global public health pioneer Dr Seth Berkley as scientific advisor to the CEO.
In the new role, Dr Berkley is to guide the firm's strategic manufacturing and supply chain efforts, and the go-to-market strategy including quality, distribution and pricing.
Dr Berkley is an infectious disease epidemiologist and has expertise in global health. He has worked as CEO of Gavi. He also co-founded COVAX and International AIDS Vaccine Initiative. He has served at the Special Pathogens Branch of the US Centers for Disease Control and Prevention (CDC), the Massachusetts Department of Public Health, the Ministry of Health of Uganda and the Rockefeller Foundation.
Steven Damon, Micron Biomedical CEO, said: "Vaccines are the most effective weapons we have against disease and no one has been more effective than Dr. Seth Berkley in leading the world's most successful distribution of life-saving vaccines. As Micron pivots to mass manufacturing and expanded vaccine and therapeutic indications, Dr. Berkley's expertise will bring game-changing perspectives that will allow us to even further accelerate efforts to make pharmaceuticals more accessible, more affordable and more convenient through our microarray technology."
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Gilead study suggests lenacapavir superior to Truvada
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Allurion's Gastric Balloon introduced at Somerset NHS Foundation Trust for pre-surgical weight loss
Takeda's HYQVIA gains FDA approval for CIDP maintenance therapy
ANGLE signs USD250,000 contract with Eisai for HER2 assay pilot study
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring